BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LY4065967 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LY4065967\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07641517-8814@assetmemo.bio
DTSTAMP:20261121T005449Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:LY4065967: Phase 2 readout est. (NCT07641517)
DESCRIPTION:LY4065967\, phase 2.\nStudy: A Chronic Pain Master Protocol (CP
 MP): A Study of LY4065967 in Participants With Osteoarthritis Pain\nEstima
 ted primary completion: April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ly4065967#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07641517
URL:https://assetmemo.bio/drug/ly4065967#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641504-8814@assetmemo.bio
DTSTAMP:20261121T005449Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:LY4065967: Phase 2 readout est. (NCT07641504)
DESCRIPTION:LY4065967\, phase 2.\nStudy: A Chronic Pain Master Protocol (CP
 MP): A Study of LY4065967 in Participants With Chronic Low Back Pain\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ly4065967#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07641504
URL:https://assetmemo.bio/drug/ly4065967#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05986292-8814@assetmemo.bio
DTSTAMP:20261121T005449Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:LY4065967: Phase 2 readout est. (NCT05986292)
DESCRIPTION:LY4065967\, phase 2\, Diabetic Peripheral Neuropathic Pain.\nSt
 udy: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-
 Appendices (ISAs) in Participants With Chronic Pain\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ly4065967#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05986292
URL:https://assetmemo.bio/drug/ly4065967#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285018-8814@assetmemo.bio
DTSTAMP:20261121T005449Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:LY4065967: Phase 2 readout est. (NCT07285018)
DESCRIPTION:LY4065967\, phase 2\, Diabetic Peripheral Neuropathic Pain.\nSt
 udy: A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Partic
 ipants With Diabetic Peripheral Neuropathic Pain\nEstimated primary comple
 tion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ly40
 65967#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07285018
URL:https://assetmemo.bio/drug/ly4065967#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
